(Q34268119)

English

F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Ira Winer

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Shouyan Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Yong-Eun Koo Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Wenzhe Fan

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Yusong Gong

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Daniela Burgos-Ojeda

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Greg Spahlinger

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

R Kopelman

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Ronald J Buckanovich

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

19 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

8674-8683

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Tissue-penetrating delivery of compounds and nanoparticles into tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Degradable cisplatin-releasing core-shell nanogels from zwitterionic poly(beta -aminoester)-graft-PEG for cancer chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Tumor vascular proteins as biomarkers in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Brain cancer diagnosis and therapy with nanoplatforms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

6 July 2018

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

28 October 2018

Vascular targeted nanoparticles for imaging and treatment of brain tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

28 October 2018

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

28 October 2018

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

28 October 2018

Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

28 October 2018

Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970692

28 October 2018

Vascular leukocytes contribute to tumor vascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/20959470

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/20959470

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of bevacizumab in ovarian cancer--an evolving story

1 reference

https://pubmed.ncbi.nlm.nih.gov/20959470

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/0008-5472.CAN-10-1917

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34268119&oldid=1958822760"